Summary of results B: Pain‐free at one hour in placebo‐controlled studies
Route of administration	Dose (mg)	Number of		Number with outcome/total		Percent with outcome		Relative benefit (95% CI)	NNT (95% CI)
		Studies	Participants	Active	Placebo	Active	Placebo
In participants with moderate or severe baseline pain
Oral	50	5	1735	45/902	16/833	5	2	2.6 (1.5 to 4.7)	33 (21 to 73)
Oral	100	6	3176	158/2216	15/960	7	2	4.0 (2.3 to 6.8)	18 (15 to 24)
Subcutaneous	4	2	664	134/411	16/253	33	6	4.7 (2.8 to 7.7)	3.8 (3.2 to 4.8)
Subcutaneous	6	16	3592	905/2198	99/1394	41	7	5.6 (4.6 to 6.8)	2.9 (2.7 to 3.2)
Intranasal	20	2	499	39/320	4/179	12	2	6.2 (2.2 to 18)	10 (7.1 to 17)
In participants with mild baseline pain
Oral	50	5	1246	161/624	87/622	26	14	1.9 (1.5 to 2.4)	8.5 (6.2 to 13)
Oral	100	5	1240	189/618	87/622	31	14	2.2 (1.8 to 2.8)	6.0 (4.7 to 8.3)